bs-2343R

[Primary Antibody]

EPO Rabbit pAb

BiOSS
ANTIBODIES

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

— DATASHEET

Host: Rabbit

Isotype: IgG

Clonality: Polyclonal

GeneID: 2056

SWISS: P01588

Target: EPO

Immunogen: KLH conjugated synthetic peptide derived from human Erythropoietin: 101-193/193.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.

Background: Human erythropoietin is member of the EPO/TPO family and encodes a secreted, glycosylated cytokine hormone composed of four alpha helical bundles. The protein is found in the plasma and regulates red cell production by promoting erythroid differentiation and initiating hemoglobin synthesis. This protein also has neuroprotective activity against a variety of potential brain injuries and antiapoptotic functions in several tissue types. It is produced by kidney or liver of adult mammals and by liver of fetal or neonatal mammals.

Applications: **WB** (1:500-2000)
IHC-P (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)

Reactivity: Human, Rat (predicted: Mouse, Rabbit, Pig, Sheep, Cow, Dog, Horse)

Predicted MW.: 28 kDa

Subcellular Location: Secreted

— VALIDATION IMAGES

Sample: Lane 1: Rat Liver tissue lysates Lane 2: Human HepG2 cell lysates Primary: Anti-EPO (bs-2343R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 28 kDa Observed band size: 33 kDa

Tissue/cell: Rat kidney tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-EPO Polyclonal Antibody, Unconjugated(bs-2343R) 1:200, overnight at 4℃, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining

— SELECTED CITATIONS

- **[IF=6.6]** Ling Tang. et al. Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy. INT J NANOMED. 2024 六月 04 IHC ;Mouse. 38859958

- **[IF=7.338]** Giraud S et al. The inhibition of eIF5A hypusination by GC7, a preconditioning protocol to prevent brain death‐induced renal injuries in a preclinical porcine kidney transplantation model. Am J Transplant. 2020 Dec;20(12):3326-3340. WB ;Pig. 32400964

- **[IF=6.458]** Yi-Fang Wu. et al. VEGF loaded nanofiber membranes inhibit chronic cerebral hypoperfusion-induced

cognitive dysfunction by promoting HIF-1a/VEGF mediated angiogenesis. NANOMED-NANOTECHNOL. 2023 Feb;48:102639 WB ;Rat. 36549557

- **[IF=4.8]** Haipiao Huang. et al. Jian-Pi-Yi-Shen formula ameliorates renal fibrosis-induced anemia in rats with chronic kidney disease. J ETHNOPHARMACOL. 2024 Dec;335:118607 IHC ;Rat. 39069029

- **[IF=4.5]** Mo Liu. et al. Methotrexate-modified docetaxel liposome targeting with ginsenoside Rh2 as a membrane stabilizer for the treatment of ovarian cancer. J DRUG DELIV SCI TEC. 2024 Sep;98:105917 IF ;Mouse. 10.1016/j.jddst.2024.105917